Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma
Conditions
Interventions
RO7293583
Tocilizumab
+2 more
Locations
14
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Thomas Jefferson University Hospital;Medical Oncology
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Peter Maccallum Cancer Institute; Clinical Trial Unit
Melbourne, Victoria, Australia
UZ Antwerpen
Edegem, Belgium
Start Date
October 28, 2020
Primary Completion Date
July 28, 2022
Completion Date
July 28, 2022
Last Updated
October 3, 2022
NCT05111574
NCT05039801
NCT06391099
NCT07076550
NCT06673095
NCT06007690
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions